Synapsoft logo
AI Insights from Disclosures
Searching...
EyeGene,Inc 185490
Searching...

Company Summary

Quarterly Performance Revenue Operating Margin

Market Sentiment

※ Click the graph to view AI analysis information for that month.
Revenue
Consolidated
Separate
Operating Income
Consolidated
Separate
Net Income
Consolidated
Separate

Financials

Excel

No financial data is available for this period.
~
Quarterly
Annual
No data is available for this period.

*Values beyond the fourth decimal place of the unit are displayed as '0/-0'

Financial Indicator Forecast

※ These forecasts are simple AI estimates based on historical data and may differ from actual results.

Company Overview

as of June 2026
EyeGene,Inc is a biotech new drug development company that uses the human-derived recombinant protein 'EGT022' to develop a treatment for diabetic retinopathy, and has established its own adjuvant platform technology to research premium vaccines based on it. In the vaccine field, the company is conducting clinical-stage development of an mRNA-based 'COVID-19 preventive vaccine', and is making significant efforts to establish the platform technology for its 'EG-R' system, which uses cationic liposomes as an mRNA delivery vehicle.
Representative Director Choi Seokgeun
Founded June 23, 2000
Corporation Type KOSDAQ
Industry Classification Research and experimental development on medical sciences and pharmacy
Corporate number 11011-2005018
Business number 101-81-60412
Phone Number 02-322-1687
Fax Number 02-302-4359
Company Address 13 Yangjipyeon 2-ro, Uiwang-si, Gyeonggi-do
Products & Services

Financial Health

Executives

Employees

Shareholders

Industry revenue

Disclosures

Comments

0 / 255

AI Assistant